Discover key insights from Gilead Sciences' Q2 2025 earnings call, featuring Yeztugo's groundbreaking launch, upward guidance revisions, and strong ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

Scientific breakthroughs are fueling new hope in women’s health. But experts warn that persistent gaps in funding and access could stall that progress.

The very sayings that once shaped our conduct could be reimagined to reshape our mindsets: “Do not sweep the house at night, ...

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Health Minister Aaron Motsoaledi told Bhekisisa’s TV show, Health Beat, in July, that he “would strongly consider” a ministerial advisory committee (MAC), like the one we had during the COVID pandemic ...

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

A study on long-acting ART shows 92% viral suppression among HIV-1 viremia patients in the U.S. South, offering hope for high ...

Biotech bigwig Gilead Sciences, Inc. (GILD) is scheduled to report second-quarter 2025 results on Aug. 7, after market close.

The district, which serves nearly 20,000 students in the western Coachella Valley, welcomed a new superintendent ahead of the 2025-26 school year.